Furthermore, our findings suggest that inclusion of Akt inhibition (to block pro-survival signaling) with (S)-crizotinib may provide an effective and novel combination therapy for GC in clinical settings with minimal off-target effects. This evidence concerns the gene AKT1 and gastric cancer.